These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35856239)

  • 1. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
    Davies A; Kater AP; Sharman JP; Stilgenbauer S; Vitolo U; Klein C; Parreira J; Salles G
    Future Oncol; 2022 Aug; 18(26):2943-2966. PubMed ID: 35856239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 treatment for B-cell malignancies: current status and future directions.
    Klein C; Jamois C; Nielsen T
    Expert Opin Biol Ther; 2021 Feb; 21(2):161-181. PubMed ID: 32933335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on obinutuzumab in the treatment of B-cell malignancies.
    Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
    Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab in hematologic malignancies: lessons learned to date.
    Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
    Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Seiter K; Mamorska-Dyga A
    Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
    Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
    Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
    Said R; Tsimberidou AM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.